The Bulletin
The Times


.

Triple agonist UBT251 showed a mean HbA1c reduction of up to 2.16% after 24 weeks in phase 2 trial in Chinese patients with type 2 diabetes

  • Written by The Bulletin
  • UBT251 is a triple agonist of the receptors for GLP-1, GIP and glucagon (triple G), being jointly developed by United Biotechnology and Novo Nordisk
  • In a phase 2 trial in Chinese people with type 2 diabetes, UBT251 showed a mean HbA1c reduction of up to 2.16%, and a mean body weight reduction of up to 9.8% after 24 weeks, showing improvements relative to placebo and semaglutide 1 mg
  • The safety and tolerability profile of UBT251 appeared consistent with what has been observed in other clinical trials with triple-G agonists.

Read more: Triple agonist UBT251 showed a mean HbA1c reduction of up to 2.16% after 24 weeks in phase 2 trial...

hacklink hack forum hacklink film izle hacklink z-libGalabetplay Royal ReelsRoyal Reels pokiesRoyal Reels pokiesRoyal Reels loginBoss Rummycasinos not on gamstopnon gamstop casinos ukcasinos not on gamstopnon gamstop casinocasinos not on gamstoponline gamblingbest casinos not on gamstopgambling sites not on gamstopgambling sites not on gamstopPadişahbetjojobetRoyal reelsThe PokiesBetpipoBetpipoVipparkPadişahbetGalabetjojobetcasibomcasibomcasinos not on gamstopnon uk casinosnot on gamstopcasinos not on gamstopcasinos non gamblock ukiptv satın aliptv satın alholiganbetcasibomjojobetjojobetbetjuvepokerklascasibomcasibom